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Abstract
Background: Deletion of some Toll-like receptors (TLRs) affords protection against cerebral ischemia, but disruption
of their known major downstream adaptors does not. To determine whether compensation in the production of
downstream effectors by one pathway when the other is disrupted can explain these findings, we examined
cytokine/chemokine expression and inflammatory infiltrates in wild-type (WT), MyD88−/− and TRIF-mutant mice
following permanent middle cerebral artery occlusion (pMCAO).
Methods: Cytokine/chemokine expression was measured with a 25-plex bead array in the serum and brains of all
three groups of mice at baseline (no surgery/naïve) and at 3 hours and 24 hours following pMCAO. Brain
inflammatory and neutrophil infiltrates were examined 24 hours following pMCAO.
Results: IL-6, keratinocyte chemoattractant (KC), granulocyte colony-stimulating factor (G-CSF) and IL-10 were
significantly decreased in MyD88−/− mice compared to WT mice following pMCAO. Significantly, decreased levels of
the neutrophil chemoattractants KC and G-CSF corresponded with a trend toward fewer neutrophils in the brains
of MyD88−/− mice. IP-10 was significantly decreased when either pathway was disrupted. MIP-1α was significantly
decreased in TRIF-mutant mice, consistent with TRIF-dependent production. MyD88−/− mice showed elevations of a
number of Th2 cytokines, such as IL-13, at baseline, which became significantly decreased following pMCAO.
Conclusions: Both MyD88 and TRIF mediate pathway-specific cytokine production following focal cerebral
ischemia. Our results also suggest a compensatory Th2-type skew at baseline in MyD88−/− mice and a paradoxical
switch to a Th1 phenotype following focal cerebral ischemia. The MyD88 pathway directs the expression of
neutrophil chemoattractants following cerebral ischemia.
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Background
Stroke remains a leading cause of death and disability in
many parts of the world, including the United States,
and approved therapies are currently limited. At the cel-
lular level, a number of mechanisms, including inflam-
mation, play a key role in the pathogenesis of a host of
neurological diseases and acute cerebral ischemia.
Therefore, a potential approach to therapy includes at-
tenuating the inflammatory damage that results from
cerebral ischemia. In this regard, it is important to study
and understand key signal transduction elements in
pathways such as the Toll-like receptor (TLR) signaling
pathway that lead to activation of major transcriptional
mediators of inflammation (i.e. NF-κB and activator pro-
tein 1) [1].
The TLR signaling pathway is evolutionarily conserved
across several species and was initially identified as im-
portant in the immune response to infection. Subse-
quently, the TLR signaling pathway has been shown to
play a pivotal role in the inflammatory response follow-
ing ischemia-reperfusion in several organ systems [2,3].
TLRs recognize both exogenous pathogen-associated
molecular patterns (PAMPs) on infectious organisms
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and endogenous danger-associated molecular patterns
(DAMPs) associated with tissue stress or injury [4,5].
The role of different TLRs in cerebral ischemia has been
studied extensively [6-8], but the accompanying down-
stream TLR signaling events remain poorly understood.
Recently, we found no significant differences in infarct
size or neuron survival in models of focal, global or
in vitro ischemia in mice with deletions or mutations of
the downstream TLR signaling adaptor molecules
Myeloid-dependent protein-88 (MyD88) and Toll/inter-
leukin 1 receptor domain-containing adaptor-inducing
interferon β (TRIF). In contrast, interestingly, assess-
ment of infarct sizes showed trends toward being larger
in MyD88−/− and TRIF-mutant mice (hereafter referred
to as TRIF) compared to wild type (WT) following focal
ischemia [9].
Furthermore, our previous results, as well as those of
others, suggest that downstream TLR signaling may be
organ-specific: different in the brain compared to the
periphery [9-12]. As a result, these studies were further
extended to characterize the cytokine production profile
in response to downstream TLR signaling following
cerebral ischemia. We studied the cytokine/chemokine
profile via the MyD88-independent (TRIF) pathway and
the MyD88-dependent pathway, which mediates down-
stream TLR signaling via all TLRs except TLR3. This
was evaluated by simultaneous determination of the
levels of 25 cytokines and chemokines in the brains and
sera of MyD88−/− and TRIF-mutant compared to WT
mice. Cytokine and chemokine analysis was performed
at baseline and at different time points following focal
cerebral ischemia. To complement our current studies,
we also determined, in parallel, the inflammatory infil-
trate in the brains of mice subjected to permanent mid-
dle cerebral artery occlusion (pMCAO). The evaluation
of inflammatory infiltrate was performed at 24 hours,
since neutrophils have been shown to be abundant at
this time point in models of murine pMCAO as used in
our study [13,14].
In the present article, we report that cerebral ischemia
leads to specific downstream adaptor-dependent produc-
tion of cytokines and chemokines. In addition, import-
antly, our present studies show that specific downstream
TLR adaptors control the secretion of neutrophil
chemoattractant chemokines that direct the migration of
neutrophils to the site of ischemia. Interestingly, we also
demonstrate that mice with disruption of one of the
major downstream signaling TLR pathways have an un-
expected shift in network dynamics that results in a spe-
cific baseline cytokine profile that may be maladaptive
toward the innate immune response to cerebral ische-
mia. Overall, these studies provide in-depth and novel
insights into the complex downstream TLR signaling
events following focal cerebral ischemia.
Materials and methods
Animals
The inclusion criteria for the mice in our MCAO studies
were (1) male, (2) ages 12 to 16 weeks old and (3) no ob-
vious signs of infection. Female mice, mice younger than
12 weeks or older than 16 weeks of age, and mice with
signs of bite wounds or other signs of infection were
excluded from the study. Mice were selected at random
from cages for inclusion in the study. Breeder pairs for
MyD88−/− mice were obtained from the Institute for Sys-
tems Biology, Seattle, WA, USA. MyD88−/− mice (here-
after referred to as MyD), have deletions in exons IV and
V encoding the carboxyl terminal portion of the MyD88
gene, which contains the Toll/interleukin 1 receptor (TIR)
domain required for downstream signaling [15]. WT
C57BL/6J and TRIF-mutant mice were obtained from The
Jackson Laboratory (Bar Harbor, ME, USA). TRIF-mutant
mice have a single base pair deletion predicted to remove
24 amino acids from the carboxyl terminus of the protein
[16]. Average weights for animals were as follows: WT,
28.7± 2.5 g; MyD, 29.5± 2.4 g; and TRIF, 27.1± 1.6 g. All
mice were housed and bred at the National Institute of
Neurological Disorders and Stroke (NINDS) Animal Care
facility under 12-hour light and dark cycles. Animals had
free access to food and water both pre- and post surgery.
All animal procedures were approved by the NINDS Ani-
mal Care and Use Committee.
Focal ischemia
pMCAO was carried out as previously described [9].
Briefly, anesthesia was induced and maintained with iso-
flurane, and the distal left MCAO was cauterized by
means of an electrocoagulator (ICC 200; ERBE Elektro-
medizin, Tübingen, Germany). Rectal temperature was
maintained at 37°C in mice from all three groups during
surgery by using a heating pad. No mice died during or
after MCAO surgery. The surgeon who performed the
MCAO surgery (YM) was blinded to the genotype of the
animal. Mouse tails were color-coded for identification
(by BF) during pMCAO surgery. One MyD88−/− mouse
was excluded from cytokine analysis because of
hemorrhage during MCAO surgery. The decision to
exclude this animal from analysis was made by the
surgeon, who was unaware of the group to which the
animal belonged. Euthanasia was carried out with le-




Twenty-seven mice were used for brain and serum cyto-
kine/chemokine analysis, comprising nine per group for
WT, TRIF and MyD88−/−. Each group of nine mice con-
sisted of three mice each without surgery (baseline)
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three mice at 3 and three mice at 24 hours following
pMCAO.
Immunohistochemistry
Immunohistochemical studies were performed 24 hours
following pMCAO. There were a total of nine mice: three
per group for WT, TRIF-mutant and MyD88−/− mice.
Sample preparation for cytokine/chemokine analysis
Serum
Mice were euthanized at the above-mentioned time
points. Whole blood was collected via cardiac puncture,
transferred into serum gel microtubes (SARSTEDT AG &
Co, Nümbrecht, Germany) and allowed to coagulate at
room temperature for at least 20 minutes before centrifu-
gation at approximately 6,000 g for 10 minutes. The sepa-
rated serum was stored at −80°C until further analysis.
Brain homogenate
At the time points indicated above, the same mice from
which serum had been collected were euthanized, and
the subcortical structures were removed from ischemic
and non-ischemic cortices and stored at −80°C until
analysis. Subsequently, brain tissues were homogenized
in ice-cold 1× phosphate-buffered saline (PBS) (pH 7.4),
containing 1× protease inhibitor cocktail (Sigma-Aldrich,
St Louis, MO, USA) and 0.2% Triton X-100 (Sigma-
Aldrich), for 30 seconds, using an IKA T 10 basic
homogenizer (IKA Works, Wilmington, NC, USA). The
resulting homogenates were centrifuged at 15,000 g for
30 minutes at 4°C, and supernatants were stored at −80°
C until cytokine analysis.
Cytokine determination by 25-plex magnetic bead panel
Serum and extracts from homogenized brains were ana-
lyzed simultaneously for levels of 25 mouse cytokines
and chemokines using the Milliplex MAP 25-plex pre-
mixed mouse cytokine/chemokine magnetic bead panel
(Millipore), according to manufacturer’s instructions.
The 25 cytokines and chemokines analyzed included
G-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7,
IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17,
IP-10, KC, MCP-1, MIP-1α, MIP-1β, MIP-2, RANTES and
TNF-α. Briefly, 25 μl of premixed magnetic beads conju-
gated to antibodies for all 25 analytes were added to
each well of a 96-well, flat-bottomed plate containing
25 μl of brain or serum. Samples diluted 2:1 in assay
buffer. Plates were protected from light and incubated
on an orbital shaker for 2 hours at room temperature.
Incubation was followed by a wash step (three times
with 200 μl of wash buffer) on a magnetic plate washer.
Detection antibodies (25 μl) were added to each well,
and plates were reincubated with agitation for 1 hour at
room temperature. Streptavidin-phycoerythrin (25 μl)
was added to each well, and plates were reincubated
with agitation for another 30 minutes, followed by a
final wash step. Magnetic beads were resuspended in
sheath fluid and assayed on a Luminex 100 xMAP tech-
nology machine (Luminex, Austin, TX, USA) using Bio-
plex Manager 6.0 software. Standard curves were
generated for each cytokine/chemokine using standards
included in each kit. The median fluorescence intensity
for each analyte was calculated using a four- or five-
point logistic parameter curve. Chemokine/cytokine
levels below the level of detection of the assay were cal-
culated using a default value of 0 pg/ml for that particu-
lar analyte.
Immunohistochemistry
Brains were removed from a separate group of mice for
immunohistochemical studies 24 hours after pMCAO,
quickly frozen on dry ice and stored at −80°C until fur-
ther analysis. Brains sections (16 μm) were fixed with 2%
buffered formaldehyde (Mallinckrodt Chemical Co, St
Louis, MO, USA) in PBS at 4°C for 8 minutes. Endogen-
ous peroxidase was quenched using hydrogen peroxide
(0.3%) in methanol for 20 minutes. Bovine serum albu-
min (Sigma-Aldrich) and 10% normal serum, from the
originating species of the secondary antibody, were used
for blocking. Subsequently, blocked sections were incu-
bated with primary antibody overnight for 18 to 24 hours
at 4°C and with secondary antibody at room temperature
for up to 1.5 hours. Immunoreactivity with primary anti-
body was visualized with avidin-biotin staining (ABC kit;
Vector Laboratories, Burlingame, CA, USA) and diami-
nobenzene (DAB) staining (Vector Laboratories). Primary
antibodies used were anti-Ly6B.2 (cat. no. MCA771GA,
2 μg/ml; AbD Serotec, Raleigh, NC, USA and anti-CD45
(cat. no. AF114, 2 μg/ml; R&D Systems, Minneapolis,
MN, USA) for neutrophils and leukocytes, respectively.
Secondary antibodies included biotin-conjugated don-
key anti-rat (cat. no. 712-066-153) and donkey anti-goat
(cat. no. 705-066-147) at 1:3,000 concentrations (both
from Jackson Immunoresearch Laboratories, West
Grove, PA, USA) for anti-Ly6B.2 and anti-CD45,
respectively.
Nonspecific immunoreactivity with primary antibodies
was determined by the lack of DAB staining in negative
controls incubated with normal immunoglobulin G derived
from the species of the primary antibody. Specific antibody
immunoreactivity was determined by the presence of DAB
staining in stained sections incubated with primary anti-
body. Primary antibody immunoreactivity in sections from
WT mice were compared to those from MyD88−/− and
xTRIF-mutant mice brain sections. The number of neutro-
phils or leukocytes per high-powered field (10×) were
counted by two independent investigators (BF and M L), and
the averages of these counts were used for data analysis.
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Statistical analysis
Three mice per time point and nine animals per group
were used in MCAO studies to obtain statistically
analyzable data on variability with regard to cytokine pro-
duction following pMCAO among the different groups of
mice. Comparison of means among experimental groups
was done using the nonparametric Kruskal-Wallis method
(StatView version 5.0 software; SAS Institute, Cary, NC,
USA). Nonparametric Mann–Whitney U statistics was
used for comparison of means between two groups. Dif-
ferences among groups were expressed as means ± SD
and considered significant if p< 0.05.
Results
MyD88-dependent cytokines/chemokines in brain and
serum following pMCAO
IL-6, KC and G-CSF were all produced in a MyD88-
dependent manner in the serum, as illustrated by signifi-
cantly decreased levels of these cytokines/chemokines in
MyD88−/− mice compared to WT mice following pMCAO
(Table 1 and Figure 1A). The same pattern was seen in the
brain, where the levels of these same cytokines and chemo-
kines were significantly attenuated in MyD88−/− mice com-
pared to WT mice following focal cerebral ischemia
(Table 1 and Figure 1B). Interestingly, however, the signifi-
cant decreases in the levels of these MyD88-dependent
cytokines/chemokines occurred in spite of abnormal eleva-
tions, at baseline, of cytokines such as IL-6 in the serum of
MyD88−/− mice, regardless of whether the cytokine/chemo-
kine in question increased or decreased with ischemia
(Figure 1A). Levels of chemokines such as KC were com-
parable at baseline in all three groups of mice, but signifi-
cantly decreased in MyD88−/− mice, compared to WT mice
following pMCAO, indicative of MyD88-dependent pro-
duction of this chemokine (Figure 1A). In addition, of inter-
est, some chemokines, such as G-CSF, were significantly
decreased in serum at baseline in MyD88−/− mice and also
significantly decreased compared to WT with ischemia
(Figure 1A). Furthermore, of note, serum G-CSF levels
decreased in the serum following pMCAO at the same time
point at which they were increasing in the brain following
focal ischemia (Figures 1A and 1B).
Table 1 MyD88-dependent cytokines/chemokines following permanent middle cerebral artery occlusion
Location WT MyD88−/− TRIF p-value
Serum (pg/ml)
IL-6 Baseline 24.7 ± 15.2 83.3 ± 69.5 30.9 ± 28.7 n.s.†
3 hours 205.2 ± 19.8 ("8.3) 59.9 ± 3.9 (#1.4) 130.9 ± 50.7 ("4.2) 0.027,* <0.05†
24 hours 91.5 ± 12.6 37.3 ± 18.7 62.9. ± 21.0 <0.05†
KC Baseline 88.5 ± 19.4 81.1 ± 12.3 70.3 ± 29.9 n.s.†
3 hours 758.8 ± 164.4 ("8.6) 182.5 ± 47.9 ("2.3) 595.1 ± 291.3 ("8.5) <0.05†
24 hours 208.1 ± 52.6 81.3 ± 21.1 221.3 ± 103.3 <0.05†
G-CSF Baseline 1,613.8 ± 939.8 185.7 ± 54.6 1,965.3 ± 1,626.3 <0.05†
3 hours 980.3 ± 424.0 (#1.6) 154.3 ± 88.6 (#1.2) 787.4 ± 61.5 (#2.5) <0.05†
24 hours 1,566.7 ± 91.0 207.8 ± 133.8 1,282.7 ± 444.9 <0.05†
Brain (pg/g/ml)
IL-6 Baseline ND ND ND
3 hours 1,912.3 ± 2,665.9 182.3 ± 54.4 1,269.8 ± 1,643.7 <0.05†
24 hours 2,293.7 ± 1,986.5 1,811.9 ± 1,224.0 4,858.6 ± 5201.7 n.s.
KC Baseline 692.9 ± 461.5 108.2 ± 15.7 1,400.3 ± 879.4 0.030,* 0.034†
3 hours 3,271.3 ± 2,446.9 ("4.7) 1,230.1 ± 426.6 ("11.4) 2,405.8 ± 1,823.6 ("1.7) <0.05†
24 hours 1,066.0 ± 760.4 1,080.3 ± 168.6 1,694.2 ± 836.7 n.s.
G-CSF Baseline 16.7 ± 14.4 3.3 ± 3.8 14.2 ± 7.7 n.s.
3 hours 962.5 ± 1,272.7 ("57.6) 57.8 ± 26.3 ("17.5) 652.5 ± 749.6 ("45.9) <0.05†
24 hours 3,458.4 ± 5,056.6 505.3 ± 480.5 4,610.8 ± 3,333.3 n.s.
IL-10 Baseline 91.3 ± 85.7 195.2 ± 204.9 510.9 ± 447.3 n.s.
3 hours 1,047 ± 621.76 ("11.5) 87 ± 55.25 (#2.2) 319.1 ± 415.77 (#1.6) <0.05†
G-CSF granulocyte colony-stimulating factor, IL interleukin, KC keratinocyte chemoattractant, ND not detectable, TRIF Toll/interleukin 1 receptor domain-containing
adaptor-inducing interferon β, WT wild type.
*Significantly different between all three groups using Kruskal-Wallis test.
†Significantly different between WT and MyD88 using Mann–Whitney test.
Parentheses: Fold change compared to baseline for that particular group.
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On the other hand, in TRIF-mutant mice, levels of IL-
6, KC and G-CSF were comparable to the levels and ex-
pression patterns of these chemokines in WT mice in
serum and brain following pMCAO. These findings are
consistent with MyD88-dependent production of these
chemokines following pMCAO (Table 1 and Figure 1).
Brain IL-10 levels were significantly decreased in
MyD88−/− mice compared to WT 3 hours following
pMCAO, consistent with MyD88-dependent production
of this cytokine (Table 1).
Another chemokine that seemed to be dependent, in
part, on the MyD88 pathway in the brain following
pMCAO was IP-10. Levels of this chemokine were sig-
nificantly decreased in the brains of MyD88−/− mice at
3 hours following pMCAO (Figure 2). In the periphery,
however, production of this chemokine was more
dependent on the TRIF pathway following pMCAO
(Table 2 and Figure 2A).
TRIF-dependent cytokines/chemokines in the brain and
serum following pMCAO
IP-10 production in the brain was significantly decreased in
mice with disruption of either TRIF or MyD88 at 3 hours
following pMCAO. This suggests that both of these path-
ways contribute to the production of IP-10 following focal
cerebral ischemia (Figure 2A and 2B). However, brain levels
of IP-10 were significantly lower in TRIF-mutant mice at
both baseline and 3 hours following pMCAO. In addition,
serum IP-10 levels were significantly decreased in TRIF-
mutant mice at 24 hours following focal ischemia. These
combined findings indicate possible tissue specificity by
these adaptors and a greater contribution from the TRIF
pathway in IP-10 production (Figures 2A and 2B and
Table 2). In contrast, MIP-1α was clearly produced in a pre-
dominantly TRIF-dependent manner following pMCAO.
MIP-1α levels were significantly decreased at baseline in
TRIF-mutant mice in both the brain and serum, and subse-
quently at specific time points, following focal cerebral is-
chemia. Specifically, MIP-1α levels were significantly
decreased at 3 hours in the brain and at 24 hours in the
serum compared to WT following pMCAO (Table 2 and
Figures 2A and 2B).
Th2-associated cytokines in MyD88−/− mice compared to
baseline following pMCAO
Levels of Th2 cytokines such as IL-13 were significantly
decreased in MyD88−/− mice (P< 0.05) compared to
WT at 3 and 24 hours following focal cerebral ischemia
(Figure 3). This decrease occurred in the context of ap-
parently elevated levels of these cytokines and their asso-
ciated chemokines, such as RANTES and MIP-1α, at
baseline in MyD88−/− mice (Figures 3A and 3B). The ex-
pression of other Th2 cytokines, such as IL-6 and IL-10,
as well as Th2-associated chemokines, RANTES and
MIP-1α, followed the same pattern. The expression pat-
tern of these Th2 cytokines in MyD88−/− mice is
Figure 1 MyD88-dependent cytokines following permanent middle cerebral artery occlusion. Significantly decreased levels of IL-6 and
neutrophil chemoattractants, keratinocyte chemoattractant and granulocyte colony-stimulating factor, in MyD88−/− mice compared to wild type
(WT) at the indicated time points in serum (A) and brain (B). *P< 0.05, MyD88−/− compared to WT. N= 9 per group and n= 3 per time point.
0 hours = baseline.
Bolanle et al. Journal of Neuroinflammation 2012, 9:174 Page 5 of 11
http://www.jneuroinflammation.com/content/9/1/174
Figure 2 Toll/interleukin 1 receptor domain-containing adaptor-inducing interferon β (TRIF)-dependent cytokines following permanent
middle cerebral artery occlusion. Significantly decreased levels of inducible protein 10 (IP-10) and macrophage inflammatory protein 1α
(MIP-1α) in TRIF-mutant compared to wild type (WT) at the indicated time points in serum (A) and brain (B) following permanent middle
cerebral artery occlusion (pMCAO). IP-10 levels are also significantly decreased in MyD88−/− mice at 3 hours following permanent middle cerebral
artery occlusion. *P< 0.05, MyD88−/− or TRIF compared to WT. N= 9 per group and n= 3 per time point. 0 hours = baseline.
Table 2 TRIF-dependent cytokine/chemokines following permanent middle cerebral artery occlusion
Location WT MyD88−/− TRIF P-value
Serum (pg/ml)
IP-10 Baseline 164.8 ± 25.1 124.1 ± 17.6 147.5 ± 35.9 n.s.
3 hours 121.4 ± 11.4 105.9 ± 37.0 104.9 ± 18.9 n.s.
24 hours 164.7 ± 9.1 135.8 ± 21.9 113.9 ± 16.7 <0.05†
MIP-1α Baseline 169.3 ± 28.1 140.9 ± 153.9 41.7 ± 72.2 <0.05†
3 hours 166.4 ± 23.4 71.5 ± 62.7 100.4 ± 68.3 n.s.
24 hours 145.7 ± 22.6 6.7 ± 11.6 30.9 ± 53.5 <0.05†
Brain (pg/ml/g)
IP-10 Baseline 1,095.9 ± 159.5 985.4 ± 207.7 619.2 ± 141.2 <0.05†
3 hours 2,077.2 ± 803.6 1087.5 ± 190.4 710.5 ± 223.0 0.039,* <0.05†
24 hours 2,997.3 ± 2,074.2 5169.9 ± 3305 2,820± 1,273 n.s.
MIP-1α Baseline 1,096.3 ± 372.6 1026.1 ± 434.6 228.2 ± 395.3 <0.05†
3 hours 1,267.8 ± 210.9 891.5 ± 501.6 171.2 ± 148.7 <0.05†
24 hours 1,088.2 ± 413.6 1293.9 ± 741.1 403.1 ± 355.7 n.s.
IP-10 inducible protein 10, MIP-1α macrophage inflammatory protein 1α, TRIF Toll/interleukin 1 receptor domain-containing adaptor-inducing interferon β, WT wild
type.
*Significantly different between all three groups using Kruskal-Wallis.
†Significantly different between WT and TRIF mutant using Mann–Whitney test.
Parentheses: fold change compared to baseline for that particular group.
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consistent with a switch to a more Th1 type phenotype
following focal cerebral ischemia. Also consistent with
switching to a more Th1 phenotype was a significant in-
crease in Th1 cytokines, such as MCP-1 (P< 0.05), in
the brains of MyD88−/− mice at 24 hours, when levels
had started to decrease back to baseline in WT mice
(Figure 3B).
Inflammatory infiltrate in the brains of wild-type, MyD88−/−
and TRIF-mutant mice following pMCAO
Leukocytes
Leukocyte numbers per high-powered field (10×), were not
significantly different among brains from all three groups of
mice: WT, 42.3±20.1; MyD, 62.3± 13.2; and TRIF-mutant,
56.7± 30.3 (P=0.3607). At 24 hours following pMCAO,
robust leukocyte infiltration was observed in brains from all
three groups of mice, as shown in Figures 4A, 4B and 4C
for WT, MyD and TRIF-mutant mice, respectively.
Neutrophils
The brains of MyD88−/− mice showed fewer neutrophils
per high-powered field (10×): WT, 17.3 ± 8.0; MyD88−/−,
8.3 ± 9.3; and TRIF-mutant, 35.2 ± 24.3 (P= 0.189). In
contrast to the findings in MyD88−/− mice, we observed
the opposite pattern in the brains of TRIF-mutant mice,
in which the predominant functioning pathway is the
MyD88 pathway. Figures 5A, 5B and 5C show neutro-
phil infiltration in the brains of WT, MyD and TRIF-
mutant mice, respectively.
Discussion
This study demonstrates a distinct pattern of cytokine/che-
mokine production following focal ischemia in mice with
disruptions of MyD88 and TRIF. It also shows that the
MyD88 pathway plays a major role in the production of
neutrophil chemoattractants following focal ischemia. Pat-
terns of cytokine production in response to focal cerebral
ischemia are altered in mice with disruptions of these
downstream adaptors. These findings indicate that cyto-
kine/chemokine production following focal cerebral ische-
mia is mediated by these downstream TLR signaling
pathways. Our results also suggest a possible compensatory
skew toward the Th2 adaptive immune response at base-
line in mice with disruptions of MyD88 and a subsequent
paradoxical Th1 switch following focal cerebral ischemia.
These findings support our previous supposition that the
lack of protection against cerebral ischemia noted in
MyD88−/− and TRIF-mutant mice was not due to compen-
sation in the production of downstream effectors by either
pathway when the other was disrupted [9].
Figure 3 Th2 cytokines at baseline. (A) Abnormal elevations in levels of Th2 cytokines IL-6, IL-10 and IL-13 and (B) Th2-associated chemokines,
RANTES (regulated upon activation, normal T-cell expressed, and secreted) and macrophage inflammatory protein 1α (MIP-1α), in MyD88−/− mice
at baseline and significant decreases in levels of these cytokines at the indicated time points following permanent middle cerebral artery
occlusion (pMCAO) compared to wild type (WT). Interestingly, Th1-associated monocyte chemoattractant protein 1 significantly increased in the
brains of MyD88−/− mice 24 hours following pMCAO to when levels had started to decrease towards baseline in WT mice. *p< 0.05; MyD88−/− or
Toll/interleukin 1 receptor domain-containing adaptor-inducing interferon β-mutant compared to WT. N= 9 per group and n= 3 per time point.
0 hours = baseline.
Bolanle et al. Journal of Neuroinflammation 2012, 9:174 Page 7 of 11
http://www.jneuroinflammation.com/content/9/1/174
Serum and brain IL-6 production during focal cerebral
ischemia followed previously reported kinetics [17,18].
There was no apparent compensation in IL-6 levels by
the TRIF pathway. Overall, our current results demon-
strate that IL-6 production is MyD88-dependent follow-
ing focal ischemia. IL-6 levels were similar in mice with
disruptions of the TRIF pathway and WT mice. These
findings explain, in part, our earlier results which
showed that MyD88−/− mice were not protected against
cerebral ischemia and are in agreement with previous
reports showing no protection in mice with deficiency of
IL-6 in models of focal ischemia [18,19]. In addition, to
decreased levels of IL-6, we also observed decreased
levels of KC, the murine ortholog of human IL-8 and a
neutrophil chemoattractant [20], in MyD88−/− mice fol-
lowing focal cerebral ischemia. These results concur with
reports of KC production via the MyD88 pathway in a
model of infection [21-23] and highlights the parallels
between the innate immune response to focal ischemia,
noted in our study, and the reported innate immune re-
sponse to infection.
G-CSF, another neutrophil chemoattractant, which
was produced in a MyD88-dependent manner in our
study, has been shown to increase in the brain follow-
ing cerebral ischemia in humans [24]. However, the
specific downstream TLR adaptors that mediate its pro-
duction following cerebral ischemia have not previously
been studied. G-CSF has been reported to be neuropro-
tective following cerebral ischemia [25-28]. The pro-
duction of G-CSF in a MyD88-dependent manner
following cerebral ischemia in our current study is sup-
ported by findings of significantly reduced G-CSF levels
in MyD88−/− mice in models of infection [23]. The
observed decrease in brain levels of G-CSF and IL-6 in
MyD88−/− mice, along with the reported lack of protec-
tion against cerebral ischemia in IL-6-deficient mice
[19], may explain, in part, the absence of protection
against cerebral ischemia in these mice reported in our
previous studies [9].
The inclusion of baseline (naïve animals) cytokine/che-
mokine analysis in our study allowed us to show major
perturbations in cytokine levels in mice that did not have
surgery. This analysis permitted categorization of cyto-
kines/chemokines into Th1/Th2 groups. Our results re-
veal a paradoxical Th2 phenotype at baseline in MyD88−/−
mice that reverted to a more Th1 phenotype following
focal cerebral ischemia. This is in contrast to the normal
switch from a Th1- to a Th2-type phenotype associated
with cerebral ischemia [29]. In some cases, this abnormal
baseline elevation in MyD88−/− mice was found only in
Figure 4 Leukocyte infiltrate in the brains of (A) wild-type, (B) MyD88−/− and (C) TRIF-mutant mice 24 hours following permanent
middle cerebral artery occlusion. Inset: Graph shows the number of leukocytes per high-powered field (10×) in each group of mice. There
were no differences in leukocyte infiltrate in the brains of all three groups of mice at 24 hours following focal ischemia (p = 0.3607). N= 9 mice,
and n= 3 mice per wild type, MyD88−/− and Toll/interleukin 1 receptor domain-containing adaptor-inducing interferon β-mutant.
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serum samples and, in other cases, such as IL-10, also in
the brain. These findings are consistent with previous
results that have shown tissue specificity in cytokine pro-
duction following ischemia [30]. Interestingly, the Th2-
type phenotype at baseline in MyD88−/− mice is consistent
with previous findings that TLRs control activation of the
adaptive immune response via their role in dendritic cell
maturation [31]. Importantly, these findings seem to indi-
cate that this baseline Th2 phenotype skew in MyD88−/−
mice is not protective during acute cellular ischemic stress.
These results may have clinical implications for patients
with acute focal cerebral ischemia and an underlying
chronic inflammatory condition that predisposes them to a
Th2 skew at baseline, as observed in MyD88−/− mice.
Overall, it is noteworthy that the cytokine profile
obtained from our MyD88−/− mice following cerebral is-
chemia was similar to the cytokine profile obtained when
whole-blood cells from patients with deficiencies of
MyD88 were stimulated with specific TLR agonists [32].
This highlights the physiological relevance and possible
extrapolation of our current findings, with respect to the
cytokine production, during the innate immune response
to events occurring during cerebral ischemia in humans.
IP-10 was partially produced in a TRIF-dependent
manner in our studies. However, MIP-1α was clearly
produced in a predominantly TRIF-dependent manner
following pMCAO, as shown by MIP-1α levels that were
significantly decreased at baseline in mice with disrup-
tions of the TRIF pathway and not in WT mice or in
mice with disruptions of MyD88. Also of note, consist-
ent with disruption of the TRIF pathway was the pres-
ence of comparable levels of IL-6 in TRIF-mutant mice
and WT mice, which is evidence of a functioning
MyD88 pathway. To the best of our knowledge, expres-
sion of MIP-1α has not previously been reported to
occur via the TRIF signaling pathway following focal
cerebral ischemia.
In this study, we have demonstrated a role for the
MyD88 pathway in neutrophil migration to the site of is-
chemia by showing significant decreases in the levels of
neutrophil chemoattractants, such as KC and G-CSF, in
MyD88−/− mice following focal cerebral ischemia. A
study of inflammatory infiltrate with apparently fewer
neutrophils in the brains of MyD88−/− mice following
focal ischemia provided additional evidence in this re-
gard. These combined results strengthen our conclusion
Figure 5 Neutrophil infiltrate in the brains of (A) wild-type, (B) MyD88−/− and (C) TRIF-mutant mice at 24 h following permanent
middle cerebral artery occlusion. Inset: Graph shows the number of neutrophils per high-powered field (10×) in each group of mice. There
was a trend toward fewer neutrophils in the brains of MyD88−/− mice compared to wild-type (WT) and Toll/interleukin 1 receptor domain-
containing adaptor-inducing interferon β (TRIF)-mutant mice at 24 hours following permanent middle cerebral artery occlusion (P= 0.189). N= 9
and n= 3 mice per WT, MyD88−/− and TRIF-mutant.
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that the MyD88 pathway is involved in neutrophil mi-
gration to the site of cerebral ischemia. These findings
are in agreement with studies showing involvement of
the MyD88 pathway in neutrophil migration to the site
of infection in the context of low levels of the neutrophil
chemoattractant KC [33].
In summary, we demonstrate for the first time robust
differences in cytokine production by the two different
major arms of the TLR signaling pathways, MyD88 and
TRIF, following focal cerebral ischemia. The significance
of these findings includes the following. (1) Demonstra-
tion for the first time of new roles for the downstream
TLR adaptors MyD88 and TRIF in the production of
specific cytokines and chemokines in a model of focal
cerebral ischemia. (2) Indications that the MyD88 path-
way plays a major role in the expression of neutrophil
chemoattractants, such as G-CSF and KC, which direct
neutrophils to the site of tissue injury. (3) Observation
of a paradoxical Th1/Th2 cytokine profile when these
downstream adaptors are disrupted. These findings have
not been described previously and suggest a decreased
ability of these mice to mount an effective innate im-
mune response to focal cerebral ischemia. (4) Further-
more, we describe for the first time major perturbations
in the baseline cytokine profile in mice with disruptions
of MyD88. These findings may explain, in part, the lack
of protection against focal cerebral ischemia noted when
these downstream adaptors are disrupted. Overall, our
findings add to the current knowledge by describing new
roles for the downstream adaptors MyD88 and TRIF fol-
lowing focal cerebral ischemia and providing great
insights into the complex downstream TLR signaling
pathway.
Some of the strengths of our study include the fact
that we simultaneously tested for dynamic changes in
the levels of 25 cytokines/chemokines at baseline and at
different time points in brain and serum samples using
multiplex array methodology. This approach allowed us
to determine that the innate immune response to ische-
mic stress has striking similarities to the reported innate
immune response to stress from infection. These simi-
larities include the expression of cytokines and chemo-
kines that direct the recruitment of immune cells to the
site of injury as well as modulation of the Th1/Th2 re-
sponse. Studies are underway to determine the differential
gene expression profile in the brains of mice with disrup-
tions of MyD88 and TRIF to help shed further light on
these downstream TLR signaling events at the level of
gene expression.
Conclusions
Overall, these results provide new insights into the com-
plex downstream TLR signaling events following cere-
bral ischemia. Further studies of these downstream
signaling events are warranted to help identify unique
control points along these pathways that may help in
designing novel targeted therapies. These molecular tar-
gets may provide an approach to limit the inflammatory
damage that occurs following acute cerebral ischemia,
during which unbridled inflammation can exacerbate tis-
sue damage.
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